Biolux Technology has appointed Chuck Abraham as CEO, with Marcel Pordes transitioning to Executive Director to focus on strategic initiatives.
Biolux Technology announced the appointment of Chuck Abraham as chief executive officer, effective immediately. Marcel Pordes, who had served as CEO, will move into the role of executive director to focus on strategic partnerships, product innovation, and corporate development.
Leadership Focused on U.S. Market
This leadership transition reflects Biolux Technology’s intent to strengthen its operations and commercial growth in the United States. The company cited the U.S. market as its primary growth engine. Michael Hendricks will continue leading U.S. business development and commercial strategy, reporting directly to Abraham.
“We are entering an exciting phase for Biolux,” said Abraham. “The U.S. orthodontic community is rapidly embracing OrthoPulse as the new standard for biologically optimized treatment. Our priority is to build a strong commercial foundation in the United States—expanding access, supporting our doctors, and demonstrating the clinical and business value of integrating near-infrared therapy into everyday orthodontic care.“
Background on Chuck Abraham
Abraham is described as an experienced healthcare and medical device executive with a track record of scaling technologies in competitive markets. His focus will include accelerating commercial rollout, expanding adoption among orthodontic practices, and strengthening U.S. operations such as sales, clinical education, and digital engagement.
“The U.S. market represents a tremendous opportunity for Biolux,” said Pordes. “With OrthoPulse gaining strong traction among leading orthodontic practices, Chuck’s experience and leadership will ensure that Biolux continues to scale effectively and deliver on its promise of transforming patient care.“
About OrthoPulse
According to the company, OrthoPulse is a low-level near-infrared (NIR) light device that stimulates bone remodeling around tooth roots to support more efficient orthodontic treatment. It is FDA-cleared and clinically validated to reduce discomfort, improve predictability, and minimize treatment refinements and chair time.
“We are committed to making OrthoPulse an integral part of every orthodontic treatment plan,” added Abraham. “Our goal is simple—empower U.S. orthodontists to achieve better results, faster, while giving patients a more comfortable treatment journey.“
Photo: Biolux Technology
